NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Shares fell from $2,51 to ~$0,70 the day the TLD data was released. And it has not materially shown ANY higher price for over six months.

No claim of Optune superiority, just the fact it's Phase 3 trial was accepted for approval by the FDA and NVCR has multiple indications that Optune has been approved for. That is a material difference as NWBO took 16 years to complete a trial, 19 months to analyze data, tossed out the original primary endpoint, and manipulated the trial protocol, comparator, endpoints and SAP. NVCR didn't do that and still was able to gain multiple country approvals.